Titlebook: Cancer Management in Man; Biological Response Paul V. Woolley Book 1989 Kluwer Academic Publishers 1989 Tumor.antibiotics.biology.bone mar

Patrimony

Background on User-Defined Routines,0 and P388 leukemias, and human mammary and colon xenographs, among others (212). In addition, DDP was found to be active by several treatment schedules, against rat as well as mouse tumors, and to be active against tumors of both chemical and biological origins (169). Clinical trials of DDP first b

哪有黃油

Inoperable

真實(shí)的你

揭穿真相

esculent

Biological Response Modifiers, patients with cancer are not necessarily well prepared for the translation of biotherapy to the clinic. Biotherapeutic approaches are broad and involve a whole range of physiological responses inherent in cancer biology. The approaches needed to bring these biotherapeutic capabilities to the clinic

quiet-sleep

Purine Antimetabolites,imetabolites indeed play a very prominent role. Of 37 experimental anticancer drugs for which INDA’s were filed by the NCI during the period 1977–1983, no less than seven are purine antimetabolites (64). These experimental antipurines are:

愉快嗎

Alkylating Agents,e selectively towards a tumour cell rather than towards a normal cell. Selectivity of alkylating agent attack towards tumour cells may also be increased by clinical protection measures on normal tissues (e.g., by autologous bone marrow transplantation). The development of alkylating agent use has th

打算

Platinum Compounds,0 and P388 leukemias, and human mammary and colon xenographs, among others (212). In addition, DDP was found to be active by several treatment schedules, against rat as well as mouse tumors, and to be active against tumors of both chemical and biological origins (169). Clinical trials of DDP first b

monochromatic

Nitrosoureas,nitroso agents (81, 82 and references therein). Structure-activity studies led to the development of chloroethylnitrosoureas and observations that one analog, BCNU,* was curative against L1210 leukemia implanted intracranially or intraperitoneally (51, 105).